RYTM (Rhythm Pharma) Earnings per share for the last four quarters

Rhythm Pharmaceuticals Inc (RYTM) - corporate logo

Rhythm Pharmaceuticals focuses on peptide therapy for rare genetic metabolic disorders, leveraging strong scientific potential. This annual EPS TTM chart illustrates the effectiveness of this strategy, where 6.10 shows the current value of the metric. Operational activities require costly cold-chain air freight. A stable staff of researchers is being supplemented by new compliance experts to expand the business.

RYTM rhythmtx.com Net earnings per share (EPS TTM) (02/11/2024 - 11/16/2026)

RYTM (Rhythm Pharmaceuticals): analytical breakdowns and indicator data

Fundamental company valuation:RYTM (Rhythm Pharma)
Core merchandise of Rhythm Corp

Investors must distinguish sustainable growth from speculative spikes by evaluating the annual trend of net profit per share via the relative EPS YoY TTM chart. For Rhythm Pharmaceuticals (RYTM), which develops targeted therapies for rare forms of obesity, this indicator reflects the effectiveness of drug commercialization, where a stable range of values confirms the business's financial resilience amid regulatory risks.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS